BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Depemokimab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Depemokimab\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07828327-1527@assetmemo.bio
DTSTAMP:20261121T005632Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Depemokimab: Phase na readout est. (NCT07828327)
DESCRIPTION:Depemokimab\, phase na\, Asthma.\nStudy: Real-World Effectivene
 ss of Depemokimab in Allergic Bronchopulmonary Aspergillosis With Severe E
 osinophilic Asthma\nEstimated primary completion: 28 February 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/depemokimab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07828327
URL:https://assetmemo.bio/drug/depemokimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07671001-1527@assetmemo.bio
DTSTAMP:20261121T005632Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Depemokimab: Phase 3 readout est. (NCT07671001)
DESCRIPTION:Depemokimab\, phase 3\, Asthma.\nStudy: A Study of Depemokimab 
 in Participants of 6 to 11 Years of Age\nEstimated primary completion: 1 M
 arch 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/depemokima
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 671001
URL:https://assetmemo.bio/drug/depemokimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07701967-1527@assetmemo.bio
DTSTAMP:20261121T005632Z
DTSTART;VALUE=DATE:20270628
DTEND;VALUE=DATE:20270629
SUMMARY:Depemokimab: Phase 4 readout est. (NCT07701967)
DESCRIPTION:Depemokimab\, phase 4\, Chronic Rhinosinusitis with Nasal Polyp
 s.\nStudy: Efficacy and Safety of Depemokimab Monotherapy Without Concomit
 ant Use of Intranasal Corticosteroids (INCS) in Japanese Participants With
  Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)\nEstimated primary comp
 letion: 28 June 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /depemokimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07701967
URL:https://assetmemo.bio/drug/depemokimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05334368-1527@assetmemo.bio
DTSTAMP:20261121T005632Z
DTSTART;VALUE=DATE:20271029
DTEND;VALUE=DATE:20271030
SUMMARY:Depemokimab: Phase 3 readout est. (NCT05334368)
DESCRIPTION:Depemokimab\, phase 3.\nStudy: Depemokimab in Participants With
  Hypereosinophilic Syndrome\, Efficacy\, and Safety Trial\nEstimated prima
 ry completion: 29 October 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/depemokimab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT05334368
URL:https://assetmemo.bio/drug/depemokimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06979323-1527@assetmemo.bio
DTSTAMP:20261121T005632Z
DTSTART;VALUE=DATE:20280105
DTEND;VALUE=DATE:20280106
SUMMARY:Depemokimab: Phase 3 readout est. (NCT06979323)
DESCRIPTION:Depemokimab\, phase 3\, Asthma.\nStudy: Depemokimab Asthma Imag
 ing and Bronchoscopy Sub-Study\nEstimated primary completion: 5 January 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/depemokimab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06979323
URL:https://assetmemo.bio/drug/depemokimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06961214-1527@assetmemo.bio
DTSTAMP:20261121T005632Z
DTSTART;VALUE=DATE:20281213
DTEND;VALUE=DATE:20281214
SUMMARY:Depemokimab: Phase 3 readout est. (NCT06961214)
DESCRIPTION:Depemokimab\, phase 3\, Chronic Obstructive Pulmonary Disease.\
 nStudy: Depemokimab as an Extended Treatment Duration Biologic in Adults W
 ith Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (
 ENDURA-2)\nEstimated primary completion: 13 December 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/depemokimab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06961214
URL:https://assetmemo.bio/drug/depemokimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06959095-1527@assetmemo.bio
DTSTAMP:20261121T005632Z
DTSTART;VALUE=DATE:20281213
DTEND;VALUE=DATE:20281214
SUMMARY:Depemokimab: Phase 3 readout est. (NCT06959095)
DESCRIPTION:Depemokimab\, phase 3\, Chronic Obstructive Pulmonary Disease.\
 nStudy: Depemokimab as an Extended Treatment Duration Biologic in Adults W
 ith Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation\n
 Estimated primary completion: 13 December 2028. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/depemokimab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06959095
URL:https://assetmemo.bio/drug/depemokimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07177339-1527@assetmemo.bio
DTSTAMP:20261121T005632Z
DTSTART;VALUE=DATE:20290402
DTEND;VALUE=DATE:20290403
SUMMARY:Depemokimab: Phase 3 readout est. (NCT07177339)
DESCRIPTION:Depemokimab\, phase 3\, Chronic Obstructive Pulmonary Disease.\
 nStudy: eValuating the Efficacy and Safety of InitiatinG depemokImab earLy
  therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Infl
 ammation\nEstimated primary completion: 2 April 2029. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/depemokimab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07177339
URL:https://assetmemo.bio/drug/depemokimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07456033-1527@assetmemo.bio
DTSTAMP:20261121T005632Z
DTSTART;VALUE=DATE:20300923
DTEND;VALUE=DATE:20300924
SUMMARY:Depemokimab: Phase 3 readout est. (NCT07456033)
DESCRIPTION:Depemokimab\, phase 3\, Asthma.\nStudy: A Study of Efficacy and
  Safety of Depemokimab Compared With Placebo in Adults and Adolescents Wit
 h at Risk Type 2 Asthma\nEstimated primary completion: 23 September 2030. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/depemokimab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07456033
URL:https://assetmemo.bio/drug/depemokimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
